Literature DB >> 8640407

Differences in receptor binding of LDL subfractions.

H Campos1, K S Arnold, M E Balestra, T L Innerarity, R M Krauss.   

Abstract

Differences in low density lipoprotein (LDL) receptor-binding affinity among LDL particles of different size were examined in competitive binding assays in human skin fibroblasts and LDL (d = 1.020 to 1.050 g/mL) from subjects with a predominance of large (> or = 272 A), medium (259 to 271 A), and small (< or = 257 A) LDL. Among 57 normolipidemic subjects with LDL cholesterol (-C) levels < 160 mg/dL, binding affinity was reduced by 16% in those with predominantly large LDL and by 14% in those with small LDL compared with most subjects who had a predominance of medium-size LDL and in all LDL size subgroups in 66 subjects with LDL-C > or = 160 mg/dL. Differences in LDL receptor-binding affinity were further investigated by using LDL density subfractions (I, d = 1.026 to 1.032 g/mL; II, d = 1.032 to 1.038 g/mL; and III, d = 1.038 to 1.050 g/mL) from three subjects with predominantly large (pattern A) and small (pattern B) LDL particles. The binding affinity (Kd) of LDL-II was similar for patterns A and B (9.2 +/- 1.4 and 9.4 +/- 0.7, respectively) and 30% lower in LDL-III from both groups (P < .05). The binding affinity of LDL-I in pattern A (12.6 +/- 1.5 micrograms/mg) was lower (P < .05) than that in LDL-II and LDL-I from pattern B (8.0 +/- 2.4 micrograms/mg). After incubation with a monoclonal antibody that specifically blocked the LDL receptor-binding domain of apoE, LDL-I from two pattern B subjects showed substantially lower binding affinity (Kd = 20.0 and 19.2 micrograms/mg) than in pattern A (Kd = 13.2 and 14.2 micrograms/mg), a result consistent with our finding of a higher apoE content in pattern B LDL-I (P < .001). Thus, factors associated with variations in particle size and apoE content in LDL subclasses in normolipidemic subjects contribute to the differences in LDL receptor binding that may result in differing metabolic behavior in vivo.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8640407     DOI: 10.1161/01.atv.16.6.794

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  25 in total

Review 1.  Small, dense low-density lipoprotein: risk or myth?

Authors:  Ngoc-Anh Le
Journal:  Curr Atheroscler Rep       Date:  2003-01       Impact factor: 5.113

2.  Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib.

Authors:  Ronald M Krauss; Kathleen Wojnooski; Joseph Orr; J Casey Geaney; Cathy Anne Pinto; Yang Liu; John A Wagner; Julie Mabalot Luk; Amy O Johnson-Levonas; Matt S Anderson; Hayes M Dansky
Journal:  J Lipid Res       Date:  2011-12-17       Impact factor: 5.922

3.  Low density lipoprotein aged in plasma forms clusters resembling subendothelial droplets: aggregation via surface sites.

Authors:  Marco De Spirito; Roberto Brunelli; Giampiero Mei; Francesca R Bertani; Gabriele Ciasca; Giulia Greco; Massimiliano Papi; Giuseppe Arcovito; Fulvio Ursini; Tiziana Parasassi
Journal:  Biophys J       Date:  2006-03-13       Impact factor: 4.033

Review 4.  Influence of dietary carbohydrate and fat on LDL and HDL particle distributions.

Authors:  Patty W Siri; Ronald M Krauss
Journal:  Curr Atheroscler Rep       Date:  2005-11       Impact factor: 5.113

5.  LDL particle heterogeneity, and its association with other established cardiovascular risk factors in a young Indian industrial population.

Authors:  Ramakrishnan Lakshmy; Prabhakaran Dorairaj; Mohamad Tarik; Ruby Gupta; Kolli Srinath Reddy
Journal:  Heart Asia       Date:  2012-10-16

Review 6.  Role of ROS and RNS Sources in Physiological and Pathological Conditions.

Authors:  Sergio Di Meo; Tanea T Reed; Paola Venditti; Victor Manuel Victor
Journal:  Oxid Med Cell Longev       Date:  2016-07-12       Impact factor: 6.543

7.  Lipid composition influences the shape of human low density lipoprotein in vitreous ice.

Authors:  Andrea Coronado-Gray; Rik van Antwerpen
Journal:  Lipids       Date:  2005-05       Impact factor: 1.880

8.  Characterization of statin dose response in electronic medical records.

Authors:  W-Q Wei; Q Feng; L Jiang; M S Waitara; O F Iwuchukwu; D M Roden; M Jiang; H Xu; R M Krauss; J I Rotter; D A Nickerson; R L Davis; R L Berg; P L Peissig; C A McCarty; R A Wilke; J C Denny
Journal:  Clin Pharmacol Ther       Date:  2013-10-04       Impact factor: 6.875

9.  Phytosterol-enriched yogurt increases LDL affinity and reduces CD36 expression in polygenic hypercholesterolemia.

Authors:  Gianluca Ruiu; Silvia Pinach; Fabrizio Veglia; Roberto Gambino; Saverio Marena; Barbara Uberti; Natalina Alemanno; Davina Burt; Gianfranco Pagano; Maurizio Cassader
Journal:  Lipids       Date:  2008-11-08       Impact factor: 1.880

10.  Improved cholesterol phenotype analysis by a model relating lipoprotein life cycle processes to particle size.

Authors:  Daniël B van Schalkwijk; Albert A de Graaf; Ben van Ommen; Kees van Bochove; Patrick C N Rensen; Louis M Havekes; Niek C A van de Pas; Huub C J Hoefsloot; Jan van der Greef; Andreas P Freidig
Journal:  J Lipid Res       Date:  2009-06-10       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.